Results 41 to 50 of about 265,886 (307)
Frontiers in Immunology, 2022 Breast cancer (BC) is the most prevalent cancer in women worldwide. A systematic approach to BC treatment, comprising adjuvant and neoadjuvant chemotherapy (NAC), as well as hormone therapy, forms the foundation of the disease’s therapeutic strategy. The
Jianyu Liu +8 more
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2019 Objective To evaluate the safety, feasibility and efficacy of template-assisted 192Ir-based hypofractionated stereotactic ablative brachytherapy (SABT) combined with surgery for peripheral non-small cell lung cancer (NSCLC) patients.
SHI Xiangxiang +5 more
doaj +1 more source
Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. [PDF]
, 2019 We analyzed DCE-MR images from 132 women with locally advanced breast cancer from the I-SPY1 trial to evaluate changes of intra-tumor heterogeneity for augmenting early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS ...
Cohen, Eric +8 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background The management of clinically apparent single lesions or oligofocal nephroblastomatosis, a facultative precursor of nephroblastoma, remains debated. Methods We retrospectively analyzed 37 patients with clinically apparent single or oligofocal nephroblastomatosis (two to three lesions per kidney) among 2347 patients registered between
Nils Welter +17 more
wiley +1 more source
Frontiers in OncologySummary backgroundOur objective was to investigated the safety and feasibility of neoadjuvant treatment with PD(L)1 inhibitors and chemotherapy followed by surgery for resectable SCLC.MethodsIn this retrospective cohort study, we included patients with ...
Zhi Yang, Yan-qing Wang, Xiujun Chang
doaj +1 more source
Frontiers in Immunology, 2022 Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-
Zhengyang Yang +11 more
doaj +1 more source
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. [PDF]
, 2019 Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivity and spatial resolution that enables detection of sub-centimeter lesions and depiction of intratumoral heterogeneity.
Chien, Amy J +10 more
core +2 more sources
Molecular Oncology, EarlyView.Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova +25 more
wiley +1 more source
Frontiers in Oncology, 2023 Epidermal growth factor receptor (EGFR) mutations have been frequently detected in patients with pulmonary adenocarcinoma. EGFR Exon 19Del and 21L858R mutations are the two most common EGFR mutations.
Hongming Wang +12 more
doaj +1 more source
Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer
Molecular Oncology, EarlyView.COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann +61 more
wiley +1 more source